PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells

作     者：ZAHRA NASRPOUR NAVAEI GHAZALEH KHALILI-TANHA AMIR SADRA ZANGOUEI MOHAMMAD REZA ABBASZADEGAN MEYSAM MOGHBELI 

作者机构：Department of Medical Genetics and Molecular MedicineSchool of MedicineMashhad University of Medical SciencesMashhadIran Student Research CommitteeFaculty of MedicineMashhad University of Medical SciencesMashhadIran Medical Genetics Research CenterMashhad University of Medical SciencesMashhadIran 

出 版 物：《Oncology Research》 (肿瘤学研究（英文）)

年 卷 期：2021年第29卷第4期

页      面：235-250页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：PI3K/AKT Cancer Chemoresistance Cisplatin Chemotherapy 

摘      要：Chemotherapy is one of the main therapeutic modalities for cancer ***(CDDP),as one of thefirst-line drugs,is of great importance in the chemotherapy of various ***,a significant percentage of cancer patients are resistant to CDDP *** to the CDDP side effects on normal tissues,the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer *** molecular mechanisms and signaling pathways are associated with CDDP *** PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells to regulate various pathophysiological processes such as cell proliferation,migration,and drug *** the present review,we summarized all of the studies which have been reported on the role of PI3K/AKT pathway in regulation of CDDP *** was shown that the PI3K/AKT pathway is mainly involved in CDDP response in lung,ovarian,and gastrointestinal *** was also observed that the non-coding RNAs have a key role in CDDP response by regulation of PI3K/AKT *** review paves the way for suggesting a PI3K/AKT-related panel marker for the prediction of CDDP response in different cancer patients.